Avectas
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 1800, Cambridge, Massachu...Phone Number
(617) 444-8593Website
www.avectas.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Avectas
Avectas is a cell engineering technology company dedicated to enhancing the cost-effectiveness, manufacturing processes, and patient outcomes of next-generation cellular therapies. Their flagship product, Solupore, integrates multiple unit processes into a single consumable, streamlining operations and significantly reducing costs while enabling scalable cell therapy production. The company targets clients in the biopharmaceutical sector, particularly those involved in autologous cell therapy, by addressing challenges such as batch failures and high facility costs. Avectas aims to improve access to CAR T-cell therapies, ensuring that more patients can benefit from these advanced treatments.Explore more
Avectas Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avectas your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Avectas is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Avectas
Click to see if Avectas had a recent Job posting/layoffs
Earning: See what the market has to say on Avectas recently announced quarterly report
Product Launch: Get notified when Avectas launches new products
Check if Avectas has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Avectas has new funding data
Avectas, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Avectas
Compare insights from companies similar to Avectas, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avectas is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Avectas is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Avectas.
Avectas financials insights
Gather financial insights about Avectas, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$2.5M
2019
Series B
$10M
2020
Series C
$20M
Avectas Tech Stack
A closer look at the technologies used by Avectas
See more technologies
Most Recent Scoops
Left Company
Executive Move
Event
will be attending the 8th CAR-TCR Summit 2023 conference as an exhibitor. The event will occur from August 29 to September 1, 2023.
New Hire
Executive Move
Left Company
Executive Move
Event
Avectas News & Media
Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
DUBLIN, Ireland and CAMBRIDGE, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week, Miami Beach Convention Centre, January 17th - 20th, 2023, Booth # 331Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors
Collaboration brings together Avectas' breakthrough cell engineering technology and Inceptor Bio's CAR-T platform MORRISVILLE, N.C. and DUBLIN, Oct. 12, 2022 /PRNewswire/ -- Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce...GenScript and Avectas Team Up to Improve the Non-Viral Cell Therapy Manufacturing Process
The two biotech leaders have embarked on a research project to streamline manufacturing of non-viral CRISPR gene editing components; the goal is to improve the editing efficiency and cell viability of non-viral based cell therapies PISCATAWAY, N.J. and DUBLIN, Sept. 20, 2022 /PRNewswire/...Avectas Announces New Chief Technology Officer
DUBLIN, Aug. 2, 2022 /PRNewswire/ -- Avectas, a cell engineering technology business, is delighted to announce the appointment of Dr Justin McCue, as its new Chief Technology Officer. Dr McCue will be based in Boston and will lead the overall technological and scientific strategy for...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Avectas
Sign Up For FreeTo access detailed company insights
Avectas is a cell engineering technology company dedicated to enhancing the cost-effectiveness, manufacturing processes, and patient outcomes of next-generation cellular therapies. Their flagship product, Solupore, integrates multiple unit processes into a single consumable, streamlining operations and significantly reducing costs while enabling sc... Read More
